News from DNAtrix A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 13, 2017, 09:00 ET DNAtrix Virus Expressing T-Cell Co-stimulator OX40L (CD252) Presented at the 2017 Society for Immunotherapy of Cancer Meeting

Juan Fueyo, MD, Professor at MD Anderson Cancer Center Department of Neuro-Oncology, presented results of a comprehensive study on the oncolytic...


Jun 01, 2017, 16:00 ET DNAtrix to Present Results of DNX-2401 for Recurrent Glioblastoma at ASCO 2017

DNAtrix, a biopharmaceutical company developing oncolytic virus immunotherapies for cancer, announced today that it will present favorable safety...


May 11, 2017, 09:00 ET DNAtrix Oncolytic Myxoma Virus Eliminates Treatment-Resistant Cancer

DNAtrix, a clinical stage biotechnology company developing oncolytic viruses for cancer, today announced a podium presentation on the use of...


Apr 24, 2017, 09:00 ET Precision Intratumoral Delivery of DNX-2401 with the Alcyone MEMS Cannula

DNAtrix, a clinical stage biotechnology company developing virus-based immunotherapies for cancer, and Alcyone Lifesciences, a leader in neural...


Nov 17, 2016, 16:00 ET DNAtrix to Present Clinical Data at the 21st Annual Meeting of the Society for Neuro-Oncology

DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that two presentations updating...


Nov 08, 2016, 16:00 ET DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform

DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced it has entered into an exclusive...


Nov 01, 2016, 16:00 ET DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA

DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that the first patients have been...


Aug 04, 2016, 08:00 ET DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401

 DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced the award of a $2 million...


Jul 27, 2016, 12:40 ET DNAtrix Receives European Medicines Agency PRIME Designation

 DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that the European Medicines...


Jul 21, 2016, 09:00 ET DNAtrix Announces Successful Intratumoral Delivery of DNX-2401 via Alcyone's MEMS Cannula for the Targeted Treatment of Recurrent Glioblastoma

DNAtrix, a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer, announced the successful intratumoral...


Feb 09, 2016, 09:00 ET DNAtrix's Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation for Treating Malignant Brain Tumors

 DNAtrix, a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer, announced that its lead product,...